Needham Maintains Buy on Revolution Medicines, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $34 to $36.
October 23, 2023 | 10:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst maintains a Buy rating on Revolution Medicines and raises the price target from $34 to $36.
The news is directly about Revolution Medicines. The raised price target by Needham analyst indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100